ANTABIO

ANTABIO at #ChinaBio, building strategic partnerships in China to advance the development of our lead program #MEM_ANT3310. #MEM_ANT3310 is designed to address the urgent need for new treatments against multidrug-resistant bacterial infections in hospitalized patients. By seeking to join forces with leading Chinese partners, we aim to accelerate the development and availability of this critical therapy. Meet us at #ChinaBio to learn more about our development plans and partnering strategy in China. Gordon Waldron Rienk Pypstra Marc Lemonnier AMR Action Fund #Antabio #Partnerships #China #MEM_ANT3310 #AntimicrobialResistance #HealthcareInnovation #GlobalHealth

Join ANTABIO at #ESCMIDGlobal2025 in Vienna, Austria, from April 11-15, 2025! Discover our latest data and the exciting advancements we're making with our clinical program, #MEM_ANT3310. #MEM_ANT3310 is being developed for the treatment of serious infections such as hospital-acquired bacterial pneumonia (#HABP) and ventilator-associated bacterial pneumonia (#VABP), which can be caused by multidrug-resistant pathogens, including Carbapenem-Resistant Enterobacterales (#CRE) and Carbapenem-Resistant Acinetobacter baumannii (#CRAB). Check out the posters and presentations below, and don't hesitate to reach out to us and to our fantastic collaborators to learn more! **************************************************** #Oral_Presentation_E0475 (#TopRatedAbstract). Broad spectrum coverage of serine β-lactamase and high in vitro potency against KPC and OXA-48-like-producing Enterobacterales of meropenem in combination with the novel diazabicyclooctane β-lactamase inhibitor #ANT3310. A work conducted and presented by the University Hospital A Coruña (#CHUAC). Arena 4. Sunday 13th April, 4:15pm. #Poster_P2356. Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem with the diazabyciclooctane β-lactamase inhibitor #ANT3310. A work conducted and presented by the University Hospital A Coruña (#CHUAC) #Poster_P2447. Pharmacokinetics-Pharmacodynamics of #ANT3310, in Combination with Meropenem, Against Carbapenem-Resistant Enterobacterales Using a Neutropenic Murine Acute Pyelonephritis Model. Presented by #ICPD #Poster_P5021. Evaluation of the Activity of the Novel Antibiotic Combination #Meropenem_ANT3310 against Recent Multidrug-resistant Enterobacterales and Acinetobacter baumannii Clinical Isolates. Presented by IHMA *******************************************************************

Join us at the #EICSUMMIT25! 🌟 Meet our CEO, Marc Lemonnier, at Europe's premier event where visionary scientists, pioneering innovators, entrepreneurs, investors, and policy makers come together. 📅 Dates: April 2-3, 2025 📍 Location: Historic Tour & Taxis, Brussels Don't miss the chance to connect with Marc and discover more about ANTABIO's groundbreaking programs and investment opportunities in the #antimicrobialresistance space. #AMR #Innovation #Investment #Healthcare #Biotech #Networking European Innovation Council and SMEs Executive Agency (EISMEA) AMR Action Fund IRDI Capital Investissement BNP Paribas Turenne Groupe Relyens en France Bpifrance

We’re excited to be a member of the Presenting Company Class for the upcoming 4th East-West Biopharma Summit in Singapore. Our founding CEO Marc Lemonnier is looking forward to sharing ANTABIO’s streamlined development plans for bringing our life-saving antibacterial drug #MEM_ANT3310 to patients in Asia and the world in the coming years. #BioCenturyEastWest #antimicrobialresistance #InvestInAMR #EU_Innovation #France

We are thrilled to announce that ANTABIO will be presenting at the #GlobalIRJPM2025 event organized by KoreaBIO in marge of the #JPMorgan Healthcare Conference 2025. Join us on January 14th at 14:30 PST in San Francisco as we share our latest innovations and breakthroughs in the fight against antibiotic resistance. Don't miss this opportunity to learn more about our cutting-edge clinical program #MEM_ANT3310 and our current series C investment opportunity. See you there! #Antabio #GlobalIRJPM2025 #HealthcareInnovation #AntibioticResistance #Biotech

World AMR Awareness Week 2024 Read the EIC story, featuring ANTABIO. Progress made on our lead program #MEM_ANT3310 has been impressive, with strong support from the European Innovation Council and SMEs Executive Agency (EISMEA) #WAAW2024 #antimicrobialresistance #InvestInAMR https://lnkd.in/e5A4ecn5

Antabio is hiring a Project Manager to provide support to our Head of Program Management on the management and coordination of CMC and non-clinical development activities ! For more information: www.antabio.com/careers

We are pleased to unveil our new logo and refreshed graphic identity. Our new look represents the dynamic and forward-thinking nature of ANTABIO, as we continue to push the boundaries in the fight against #antimicrobialresistance. 🔹 New Logo: A symbol of our growth and evolution, and a reference to our field of expertise: understanding how bacteria grow, divide and express virulence/resistance factors to promote infection and cause diseases. 🔹 Graphic Identity: Modern, rigorous, and aligned with our mission to develop new drugs that can offer a lifeline to patients suffering from drug-resistant infections around the world. 👉 www.antabio.com #Antabio #NewLogo #BrandIdentity #Innovation #Growth #AMR #InvestToSaveLives

Between 2025 and 2050 #antibioticresistance is expected to kill 39 million people worldwide. Today, ANTABIO is calling on US Congress to prevent more deaths and #PassPASTEUR to combat the #superbug public health crisis. https://lnkd.in/eTmK_yc4 #PASTEURAct #AMR #antimicrobialresistance #UNGA2024

ANTABIO Announces Successful Completion of Phase 1 Clinical Study of #MEM_ANT3310 for Severe Hospital Infections ANT3310 was well-tolerated at all doses with no serious adverse events, dose-limiting toxicities or clinically relevant abnormalities reported. The ANT3310 PK parameters were consistent with those determined from studies in rodent and non-rodent species and dose-dependent increases in exposure were observed. ANT3310 and meropenem demonstrated very compatible PK with no mutual PK interaction. This positive Phase 1 data supports further patient studies of MEM-ANT3310. Read the full Press Release here: https://lnkd.in/ecEbeeU2